Vanda Pharmaceuticals Inc. filings document the company's operating results, commercial product disclosures, regulatory developments, and public-company governance. Form 8-K reports include quarterly and annual financial results, product-related events for NEREUS and BYSANTI, clinical and regulatory forward-looking language, and management communications about commercial strategy.
The company's proxy and governance filings cover director elections, board composition, executive compensation, equity awards, annual bonus and salary decisions, and related stockholder voting matters. Other current reports document board expansion, officer changes, compensatory arrangements, exhibits to press releases, and risk-oriented disclosures tied to Vanda's marketed products and development pipeline.
Vanda Pharmaceuticals President and CEO Mihael Hristos Polymeropoulos reported an open-market sale of 156,235 shares of common stock at a weighted average price of $8.1734 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the settlement of vested restricted stock units under RSU agreements.
After this transaction, the reporting person directly owned 2,704,496 shares of Vanda Pharmaceuticals common stock.
Vanda Pharmaceuticals Inc. senior vice president of business development Gunther Birznieks reported an open-market sale of 42,431 shares of common stock on March 2, 2026 at a weighted average price of $8.2659 per share. The shares were sold to satisfy tax obligations tied to the settlement of vested RSUs. After these transactions, he directly holds 494,197 shares. The sales occurred in multiple trades priced between $8.085 and $8.81 per share.
Vanda Pharmaceuticals director Honore Tage sold 30,000 shares of common stock in an open-market transaction at a price of $8.03 per share. After this sale, Tage directly owns 93,469 shares of Vanda Pharmaceuticals common stock.
Vanda Pharmaceuticals reported a Form 144 stating intended sales of Common Stock totaling 30,000 shares. The filing lists planned vesting/settlement amounts of 6,602 shares on 03/15/2024, 17,307 shares on 06/08/2024, and 6,091 shares on 03/15/2025.
Vanda Pharmaceuticals reports that the FDA has approved BYSANTI (milsaperidone) tablets for adults with schizophrenia and for acute manic or mixed episodes in bipolar I disorder. The drug is an atypical antipsychotic and a new chemical entity that rapidly converts to iloperidone, showing bioequivalence across the therapeutic dosing range.
The company highlights that milsaperidone builds on extensive Fanapt (iloperidone) data, including more than 100,000 patient-years of real‑world use, offering a novel option with a familiar safety profile. It is also being studied as a once-daily adjunctive therapy in treatment‑resistant major depressive disorder, with that study expected to complete by year‑end.
Vanda anticipates commercial availability in Q3 2026 and expects marketing exclusivity supported by regulatory data protections and U.S. patents lasting to 2044. The label carries a boxed warning about increased mortality in elderly patients with dementia‑related psychosis and details multiple safety risks typical for atypical antipsychotics.